SCM
ICPT

Sterling Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Sterling Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,314
Closed -$311K – 971
2014
Q3 		$311K Buy
+1,314
New +$335K ﹤0.01% 812
2014
Q2 		– Sell
-2,581
Closed -$851K – 948
2014
Q1 		$851K Buy
+2,581
New +$871K 0.01% 641

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sterling Capital Management's ICPT Position: Q4 2014 in Review

Sterling Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2014, closing a stake of 1,314 shares — an estimated $311K sold.

Sterling Capital Management first reported a position in ICPT in Q1 2014 and held it in 2 quarters. The position peaked at $851K in Q1 2014. 169 funds tracked by Wall St. Rank hold ICPT as of Q4 2014.

  • Sterling Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
  • Sterling Capital Management sold 1,314 Intercept Pharmaceuticals, Inc. shares in Q4 2014, an estimated $311K.
  • Sterling Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 2 quarters.
  • Sterling Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $851K in Q1 2014.
  • 169 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2014.

Based on Sterling Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.